Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: A prospective study

Sidhu, Harpreet Singh; Srinivas, Rohith; Sadhotra, Akshay

doi:10.1016/j.seizure.2017.03.007

Cited by 35 publications

(31 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, treatment with VPA predisposed obese children with idiopathic epilepsy to insulin resistance and lower adiponectin levels compared to age and gender matched obese controls [88]. VPA also induced hypoadiponectinemia and insulin resistance in previously untreated people with epilepsy [89,90]. Other studies, however, have found non-significant increases in adiponectin levels after VPA treatment [91,92].…”

Section: 6mentioning

confidence: 99%

“…Low plasma adiponectin levels are associated with obesity and T2DM [83,94]. The degree of hypoadiponectinemia is most closely associated with the degree of insulin resistance and hyperinsulinemia [89,93]. The presence of insulin resistant previously untreated females with epilepsy indicates that weight gain itself may not cause insulin resistance [89], but rather that adiponectin deficiency may promote insulin resistance and weight gain.…”

Section: 6mentioning

confidence: 99%

“…The degree of hypoadiponectinemia is most closely associated with the degree of insulin resistance and hyperinsulinemia [89,93]. The presence of insulin resistant previously untreated females with epilepsy indicates that weight gain itself may not cause insulin resistance [89], but rather that adiponectin deficiency may promote insulin resistance and weight gain. While R112C, 1164T, R221S, and H241P are missense mutations in adiponectin, the frequency of the 1164T mutation is significantly higher in people with T2DM than controls, and all subjects with the 1164T mutation had T2DM [95].…”

Section: 6mentioning

confidence: 99%

See 2 more Smart Citations

Drivers for the comorbidity of type 2 diabetes mellitus and epilepsy: A scoping review

Shlobin

Sander

2020

Epilepsy & Behavior

View full text Add to dashboard Cite

Epilepsy, a common neurologic condition, is associated with a greater prevalence of type 2 diabetes mellitus (T2DM). We examined potential drivers for the comorbidity of epilepsy and T2DM in an attempt to elucidate possible biological mechanisms underlying the development of processes in individuals. We searched PubMed and Medline up to December 2019. Our search yielded 3,361 articles, of which 82 were included in the scoping review. We reviewed articles with a focus on the association of epilepsy and T2DM, drivers, and biological mechanisms. Epilepsy is associated with obesity and obesity is associated with T2DM. Treatment with valproate (either sodium or acid) is associated with weight increase and hyperinsulinemia, while topiramate causes weight loss. People with epilepsy are less likely to exercise which is protective against obesity. Mitochondrial dysfunction and adiponectin deficiency are common to epilepsy and T2DM. One possible mechanism for the comorbidity is mitochondrial dysfunction and adiponectin deficiency which promotes epilepsy, obesity, and T2DM. Another possible mechanism is that people with epilepsy are more likely to be obese due to lack of exercise and the effects of some antiseizure medications, which makes them susceptible to T2DM due to the development of mitochondrial dysfunction and adiponectin deficiency. A third mechanism is that people with epilepsy have greater mitochondrial dysfunction and lower adiponectin levels than people without epilepsy at baseline, which may exacerbate after treatment with antiseizure medications. Future research involving a combined genetic and molecular pathway approach will likely yield valuable insight regarding the comorbidity of epilepsy and T2DM.

show abstract

Section: 6mentioning

confidence: 99%

Section: 6mentioning

confidence: 99%

Section: 6mentioning

confidence: 99%

See 1 more Smart Citation

Drivers for the comorbidity of type 2 diabetes mellitus and epilepsy: A scoping review

Shlobin

Sander

2020

Epilepsy & Behavior

View full text Add to dashboard Cite

show abstract

“…[23], которые проанализировали частоту и степень увеличения МТ, индуцированного приемом ВК в монотерапии у мужчин и женщин, страдающих эпилепсией. Было выявлено более выраженное и частое увеличение МТ у женщин, получавших ВК в монотерапии, по сравнению с мужчинами [27]. Также определили, что увеличение МТ чаще встречается у девочек пубертатного возраста, принимающих ВК [28].…”

Section: влияние пола и возраста пациента на риск вкиндуцированного уunclassified

“…Увеличение экспрессии мРНК adipoR1 в клетках печени, возможно, является благоприятной реакцией, уравновешивающей подавляемую секрецию адипонектина из адипоцитов. Полученные данные соответствуют предыдущим исследованиям [51], показавшим низкую концентрацию адипонектина у пациентов с ожирением и сахарным диабетом 2-го типа, объясняя биологическую связь между избыточной МТ и расстройствами, связанными с ней. Основываясь на результатах, полученных в исследовании H. Sidhu [52], можно предположить, что ВК индуцирует гипоадипонектинемию и это коррелирует с резистентностью к инсулину.…”

Section: влияние вк на адипокиныunclassified

Pharmacogenetic markers of metabolic disorders in the treatment with valproic acid

Drokov¹,

Lipatova²,

Shnayder³

et al. 2018

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

Эпилепсия является широко распространенным неврологическим заболеванием, характеризующимся повторными эпилептическими приступами. По приблизительным эпидемиологическим подсчетам, в мире эпилепсией страдают около 50 млн больных (т.е. до 1% населения планеты) [1]. В основе лечения заболевания лежит многолетний, а порой и пожизненный, прием противоэпилептических препаратов (ПЭП) в режиме как моно-, так и политерапии. В Российской Федерации затраты общественного здравоохранения на пациентов с эпилепсией (в 2005 г. с последующим сохранением такого объема экономических вливаний) составили около 14 млрд руб., при этом трата большей части денежных средств связана с терапией фармакорезистентных пациентов [2]. Основная цель лечения эпилепсии-достижение полного контроля над приступами при отсутствии клинически значимых нежелательных побочных реакций (НПР) [3]. Эффективность лечения зависит от множества факторов, в том числе особенностей фармакокинетики и фармакодинамики ПЭП. Даже в том случае, если ПЭП назначен в строгом соответствии с показаниями и противопоказаниями, использованы

show abstract

Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data

Nevitt

Sudell

Cividini

et al. 2022

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: A prospective study

Cited by 35 publications

References 28 publications

Drivers for the comorbidity of type 2 diabetes mellitus and epilepsy: A scoping review

Drivers for the comorbidity of type 2 diabetes mellitus and epilepsy: A scoping review

Pharmacogenetic markers of metabolic disorders in the treatment with valproic acid

Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data

Contact Info

Product

Resources

About